Human Cytokine-Induced Memory-Like Natural Killer Cells

Melissa M. Berrien-Elliott  Julia A. Wagner  Todd A. Fehniger
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Mo., USA

Key Words
Natural killer cells · Innate memory · Immunotherapy · Cytokine · Cytokine receptor · IL-12 · IL-15 · IL-18

Abstract
Natural killer (NK) cells are innate lymphoid cells that are important for host defense against infection and mediate antitumor responses. Recent reports from several laboratories have identified that NK cells can remember a prior activation event and consequently respond more robustly when re-stimulated, a property termed innate NK cell memory. NK cell memory has now been identified following hapten exposure, viral infection, and combined cytokine preactivation with IL-12, IL-15, and IL-18. Many questions in the field remain regarding the cellular and molecular mechanisms regulating memory NK cells and their responses, as well as their formation and function in mice and humans. Here we review our current understanding of cytokine-induced memory-like (CIML) NK cells that are generated by combined preactivation with IL-12, IL-15, and IL-18. These cells exhibit enhanced NK cell effector functions weeks after the initial cytokine preactivation. Further, we highlight the preclinical rationale and ongoing therapeutic application of CIML NK cells for adoptive immunotherapy in patients with hematologic malignancies.

Introduction
The mammalian immune system is comprised of both innate and adaptive arms. The innate arm constitutes a host’s first line of defense against pathogens, and consists of cells that express germ-line encoded receptors that recognize conserved pathogen-associated molecular patterns [1, 2]. The innate immune response was not thought to be substantially altered by repeated exposure to the same challenge. In contrast, the adaptive immune system provides long-lasting immunity against pathogens via antigen-specific receptors and adaptive immune memory [3, 4]. During their initial activation, T and B cells clonally expand in response to their cognate antigen. Nearly 90% of these responding cells undergo activation-induced apoptosis. The persisting pool of long-lived cells responds more robustly upon subsequent exposure to their cognate antigen, thus exhibiting a memory response [5]. For example, memory T cells exhibit increased proliferation, cytokine production, and cytotoxicity during recall responses, thereby more rapidly eliminating subsequent infections by the same pathogen. Thus, with repeated exposure to a specific pathogen, adaptive immune responses are boosted and can provide the host with lifelong antigen-specific immunity [6].

Natural killer (NK) cells are innate lymphoid cells critical for host defense against viruses and malignant cells [7–11]. This host protection relies on several important
NK cell functions. First, NK cells secrete cytokines and chemokines that activate, direct, and modify the host immune response. The prototypical cytokine released by NK cells is interferon-γ (IFN-γ). IFN-γ shapes T-cell immune responses, stimulates macrophages, upregulates MHC class I expression on antigen presenting cells, and decreases the proliferation of virally infected and malignant cells [7]. Second, NK cells are cytotoxic, with their ability to kill target cells mediated primarily by perforin and granzyme B, which are stored in cytotoxic granules [7]. These granules are exocytosed upon recognition of a target cell, a process that is tightly regulated to prevent indiscriminate killing [12].

Human NK cells originate in the bone marrow, differentiate in peripheral lymphoid tissue [13, 14], and are distinguished from other lymphoid cells by the absence of the T- and B-cell-specific markers (e.g. CD3 and CD19), and the presence of CD56 [7]. NK cells express a repertoire of germ-line encoded activating and inhibitory receptors that control their responses [15]. There are a variety of activating receptors (e.g. NKG2D and NKp46) that recognize ligands expressed on stressed, infected, or transformed cells, or antibody-opsonized targets (CD16/FcγRIIIa). Inhibitory signals arise from two main receptor families, killer cell immunoglobulin-like (KIR) and C-type lectin receptors (i.e. CD94-NKG2A), which recognize MHC class I or class I-like molecules [16]. There are two distinct human NK cell subsets identified phenotypically based on their surface density of CD56: CD56bright and CD56dim. CD56dim NK cells represent the majority of the NK cell population in the peripheral blood (80–95%) and are specialized to respond to NK cell receptor-based stimulation that results in potent killing and cytokine secretion [7, 17–19]. In contrast, CD56bright NK cells, which are the major subset of NK cells in secondary lymphoid tissues, respond primarily to cytokine receptor-based stimulation to produce abundant cytokines and chemokines, but are poorly cytotoxic at rest. The distinct biology of CD56bright and CD56dim NK cells is also reflected in differing complements of cell surface cytokine, chemokine, homing, integrin, and NK receptors [19, 20]. For example, CD56dim NK cells express both KIR and CD94-NKG2A inhibitory receptors, whereas CD56bright NK cells primarily express CD94-NKG2A. Additionally, CD16 (FcyRIIIa) is expressed on most CD56dim NK cells and a subset of CD56bright NK cells, allowing for antibody-dependent cellular cytotoxicity [19]. Within CD56dim NK cells, distinct functional subsets may be defined by maturation stage with less mature cells expressing CD94 and CD62L, but lacking CD57 [21–23]. The current view of human NK cell maturation is that CD56bright (stage IV) NK cells differentiate into CD56dim (stage V) NK cells [24]. However, the developmental relationship between the two remains controversial and it is possible that these subsets have distinct precursors [25]. Regardless, CD56bright and CD56dim represent distinct human NK cell subsets with differing physiological roles.

Traditionally, NK cells have been classified as innate effectors since they do not rearrange their DNA to express a specific, dominant activating receptor. More recently, however, evidence has emerged that challenges this paradigm, demonstrating that NK cells display properties of immunologic memory. This review summarizes mouse and human studies that have defined the concept of innate NK cell memory, with particular focus on human cytokine-induced memory-like (CIML) NK cells. Furthermore, we describe ongoing translational studies utilizing CIML NK cells for the treatment of hematologic malignancies.

**NK Cell Memory**

Several reports have described that innate NK cell-mediated memory can be generated in response to certain haptens and viruses, as well as following combined cytokine activation (fig. 1) [26]. NK cell memory was first described in response to two haptens, 2,4-dinitrofluorobenzene and oxazolone [27]. Mice lacking T and B cells, but not NK cells, exhibited specific contact hypersensitivity responses to these haptens that persisted for at least 4 weeks. Furthermore, adoptive transfer of NK cells from sensitized donors resulted in contact hypersensitivity responses in the recipients upon reexposure to that same hapten [27]. These NK cell memory responses to haptens are dependent on expression of CXCR6, a chemokine receptor critical for intrahepatic survival and homeostasis [28]. The molecular mechanism that explains the varying, yet specific hapten recall responses remains poorly understood.

A subsequent study demonstrated that murine NK cells exhibit a memory-like adaptive response following murine cytomegalovirus (MCMV) infection [29]. Specifically, NK cells bearing the activating receptor Ly49H, which recognizes the MCMV-expressed ligand m157, proliferate in response to MCMV infection. After a contraction phase, Ly49H+ NK cells persist for months. Upon isolation and ex vivo restimulation with plate-bound agonistic antibodies against NK1.1 or Ly49H, these cells rapidly degranulated and produced cytokines more robustly than MCMV-inexperienced NK cells [29]. Additionally,
adoptive transfer of these memory NK cells, compared to naïve, provided protective immunity to newborn mice, which lack mature NK cells and are thus highly susceptible to MCMV infection [29]. Subsequent studies demonstrated that virus-induced NK cell memory is dependent on the proinflammatory cytokine IL-12 [30].

Human studies have demonstrated that infection with cytomegalovirus (CMV) [31–33], hantavirus [34], or chikungunya virus [35] results in an imprinted NK cell receptor repertoire with an increased frequency of NKG2C+ NK cells. In the case of CMV, NKG2C+ NK cells expanded during acute infection and persisted for up to a year [36]. Additionally, these NKG2C+ NK cells produced significantly more IFN-γ in response to target cells than NKG2C– NK cells [31]. Furthermore, adoptively transferred NKG2C+ NK cells from CMV-seropositive persons displayed enhanced effector function against a secondary CMV challenge in the recipient compared to NKG2C+ NK cells from CMV-seronegative individuals [36]. Recent work has demonstrated that the combination of CMV-infected fibroblasts plus IL-12-producing monocytes results in the expansion of NKG2C+ NK cells in vitro [37]. In addition, the induction of CD25 and the high-affinity IL-2Rαβγ contribute to the expansion in this in vitro model, which also depends on NKG2C and HLA-E interactions. The precise parallels between MCMV-induced memory NK cells and NKG2C+ human NK cells in people with latent CMV are incompletely understood.

**Mouse CIML NK Cells**

At the same time virus-induced NK cell memory was reported, Cooper et al. [38] discovered that murine NK cells preactivated with cytokines exhibit memory-like properties. In this report, NK cells were preactivated overnight with IL-12, IL-15, and IL-18, or IL-15 alone as a control, and then adoptively transferred into syngeneic Rag1−/− recipients. Although a majority of the preactivated NK cells produced IFN-γ at the time of adoptive transfer, after weeks of rest in the recipients, IFN-γ production returned to baseline, undetectable levels. Furthermore, preactivated NK cells proliferated extensively in vivo, whereas control NK cells did not [38, 39]. After resting in vivo,
In vivo antitumor responses. Adoptive transfer and were able to mediate more effective IL-18 exhibited enhanced functionality months following Thus, mouse NK cells preactivated with IL-12, IL-15, and IL-18 for 16 h. Following removal of these cytokines, the cells were rested in vitro with a low dose of IL-15 as a survival factor. After 1–3 weeks of rest, NK cells preactivated with IL-12, IL-15, and IL-18 or double combinations of IL-12, IL-18, and IL-15 exhibited increased IFN-γ production after restimulation with cytokines or tumor target cells compared to control cells incubated with IL-12, IL-15, or IL-18 alone [41]. Because IL-2 and IL-15 both signal through the IL15Rβγc, it is likely that preactivation with intermediate levels IL-2 combined with IL-12 and IL-18 would result in memory-like NK cells; however, this has not been experimentally determined. Although gating on CD56bright versus CD56dim cell populations, particularly after >2 weeks in vitro, can be challenging, we observed enhanced IFN-γ production following cytokine preactivation by both CD56bright and CD56dim NK cell subsets, with a particularly robust effect on the CD56bright CIML NK cell subset [41]. Human CIML NK cells proliferated extensively, but maintained their capacity for enhanced recall responses even after multiple rounds of cell division tracked by CFSE dilution. Similar to mice, IFN-γ mRNA transcript levels did not differ between CIML and control NK cells, suggesting that a simple difference in the IFN-γ mRNA pool was not the mechanism responsible for enhanced IFN-γ [41]. However, in contrast to murine CIML NK cells, phenotypic differences were identified between preactivated NK cells and controls. Specifically, CIML NK cells had increased CD94, NKG2A, NKp46, and CD69 surface expression. Further, CIML NK cells were associated with reduced KIR and CD57 expression [41]. As a population, enhanced IFN-γ production by CIML NK cells was associated with expression of CD94, NKG2A, NKG2C, and CD69, and with the lack of KIR and CD57. These findings may assist in identifying CIML NK cells populations in vivo.

Additionally, human CIML NK cells were also shown to be responsive to low concentrations of IL-2, which is critical for promoting their function and proliferation in vivo [42]. The IL-2 receptor is composed of either intermediate-affinity (IL-2Rβγ) or high-affinity (IL-2Rαβγ) forms that are ligated by nanomolar and picomolar concentrations of IL-2, respectively [43, 44]. CD25 (IL-2Rα) is a critical component required to form the high-affinity receptor. CD25 is constitutively expressed at low levels by CD56bright, but not CD56dim NK cells, making CD56bright NK cells more responsive to low-dose IL-2 [7, 45]. Recently, it has been demonstrated that CD56bright and CD56dim CIML NK cells markedly upregulated CD25 in response to combined cytokine preactivation, resulting in the formation of a functional high-affinity...
IL-2 receptor (IL-2Rαβγ) that is ligated by picomolar concentrations of IL-2 [42]. In this study, provision of picomolar concentrations of IL-2 resulted in the proliferation of IL-12-, IL-15-, and IL-18-preactivated NK cells both in vitro and in vivo. Further, CIML NK cell IFN-γ production and cytotoxic capacity were enhanced by provision of picomolar concentrations of IL-2. These data suggest that combined cytokine preactivation results in CIML NK cells that are well adapted to utilize T cell-derived IL-2, or low-dose exogenous rhIL-2, to support their survival and functionality.

Recently, preclinical studies have shown that human CIML NK cells also have substantial potential as antileukemia cellular therapy [46]. Human CIML NK cells have exhibited enhanced IFN-γ production when restimulated (triggered) with leukemia cell lines or acute myeloid leukemia (AML) blasts in vitro. Additionally, granzyme B protein abundance and cytotoxicity were increased in human CIML, compared to control NK cells from the same donors [46]. However, enhanced degranulation in response to tumor targets was not observed in human CIML NK cells compared to controls [41], paralleling what has been observed in mice [38]. Thus, the enhanced antileukemic function of human CIML NK cells likely relies on a combination of increased cytotoxicity as well as enhanced IFN-γ production, but the precise effector mechanism important for antileukemia responses have not been experimentally defined. CIML NK cells may also be engrafted into immunodeficient NOD-SCID-γc−/− mice (NSG) mice and supported by low-dose rhIL-2. In this NSG xenograft model, CIML NK cells exhibited superior in vivo persistence, compared to control NK cells, following adoptive transfer [42]. Ex vivo analysis of CIML NK cells after transfer and rest in NSG mice revealed the memory-like phenotype with increased IFN-γ production following restimulation. Finally, CIML NK cells
exhibited a superior ability to control AML cells when transferred into leukemia-bearing NSG mice. These results, taken together with murine CIML NK cell cancer immunotherapy studies, provide the scientific rationale that cytokine preactivation with IL-12, IL-15, and IL-18 and administration of low-dose IL-2 will enhance the antileukemic effector function of adoptively transferred NK cells in humans.

CIML NK Cells: From Bench to Bedside

NK cells can recognize and respond to malignant tumor cells and are an important immunotherapeutic effector for cancer, particularly hematologic cancers [47–51]. The biology of NK cells makes them an outstanding candidate for anticancer therapy. First, unlike allogeneic T cells, NK cells do not induce graft-versus-host disease, and in fact may mediate graft-versus-host-disease protection [52, 53]. Second, some cancer cells can be recognized by allogeneic NK cells, and based on progress in NK cell receptor biology, haploidentical donors may be chosen to maximize the NK cell versus leukemia response. In particular, Ruggeri et al. [53] first showed that KIR-ligand mismatch, resulting in donor NK cell alloreactivity against recipient leukemia, markedly reduced AML relapse in patients receiving HLA-haploidentical hematopoietic stem cell transplants. Consistent with these findings, donor KIR haplotype is predictive of AML relapse risk in the setting of allogeneic transplantation [54, 55]. The antileukemic effector function of enriched NK cells using adoptive transfer has also been demonstrated in humans [56, 57]. For example, Miller et al. [56] transferred enriched NK cells (CD3- and CD19-depleted peripheral blood mononuclear cells) from haploidentical donors into patients with poor prognosis AML. The provision of enriched NK cells in this fashion resulted in complete remissions in about 30% of patients, but of relatively short duration. Rubnitz et al. [57] administered allogeneic NK cells to pediatric AML patients already in complete remission, and demonstrated safety and NK cell detection after the infusion. These and other studies have demonstrated that allogeneic NK cells may be safely administered to leukemia patients, but a limited complete remission rate and duration of response remain a barrier in the field. Therefore, approaches that enhance the functionality, expansion, and survival of adoptively transferred NK cells are needed.

Based on the basic and preclinical reports described above, we hypothesized that combined cytokine preactivation with IL-12, IL-15, and IL-18 resulting in CIML NK cell generation would be a safe and potentially effective strategy to translate NK cell memory into improved anti-AML NK cell responses. This hypothesis is currently being explored in a clinical trial of adoptively transferred allogeneic CIML NK cells in patients with relapsed or refractory AML (fig. 3, NCT01898793). For this first-in-human NK cell study, rel/ref AML patients are lymphodepleted using fludarabine and cyclophosphamide [56], followed by a single CIML NK cell infusion. After CIML NK cell transfer, low-dose rhIL-2 is administered for 14 days to support CIMK NK cell survival, expansion, and function based on the expression of the induced CD25 and
thus the high-affinity IL-2Rαβγ [58]. The clinical grade CIML NK cell product is generated from a single haplo-
dentical donor leukapheresis, followed by CD3 depletion and CD56 enrichment using magnetic selection. This approach typically results in ≥90% CD56+CD3− NK cells, which are activated for 12–16 h in rhIL-12, rhIL-15, and rhIL-18 in a GMP-compliant biological therapy facility. Prior to infusion, all cytokines are washed from the NK cell product to prevent transfer of proinflammatory agents to the patient. Correlative laboratory analyses are tracking donor CIML NK cell persistence, expansion, proliferation, and memory-like functionality at various time points following infusion. If this CIML NK cell adoptive therapy appears safe, clinical testing will be expanded to a larger number of AML patients to evaluate efficacy. Since CIML NK cell express CD16/FcγRIIa, provision of therapeutic antibodies or newer bispecific NK cell reagents could potentially be included to enhance specificity and triggering against other types of cancer.

Conclusions and Open Questions

Cellular-based therapies are gaining traction in the cancer immunotherapy field, including the use of NK cells for the treatment of hematologic malignancies. Human CIML NK cells have a number of properties that may be beneficial for antitumor responses, including enhanced function against leukemia, expansion in vivo, and responsiveness to low-dose IL-2 [41, 42, 46]. A clinical trial is now underway to test the safety of IL-12, IL-15, and IL-18 cytokine preactivated NK cells, which may be a safe and effective means of improving NK cell antitumor functionality in the context of adoptive therapy. It is remarkable that discovery of CIML NK cells has moved from murine models to a first-in-human trial in 5 years. However, despite these translational advances, we have a limited understanding of the molecular mechanisms governing CIML NK cell differentiation and functionality. These are important questions in the memory NK cell field since understanding memory at the molecular and cellular level may lead to new strategies to further enhance antitumor functionality.

There are also many other questions that remain to be answered. How are CIML NK cells generated during a physiologic immune response to infection or cancer? How do enhanced CIML NK cell effector functions contribute to antitumor immunity? Do accessory cells such as dendritic cells or macrophages that produce proinflammatory cytokines induce CIML NK cell function? Do CIML NK cells follow the rules of NK cell licensing, which prevents autoreactivity under homeostatic conditions [59]? Can CIML NK cells out-compete regulatory T cells for limiting amounts of IL-2, impeding a known brake on NK cell responses? What is the relationship of CIML NK cells to the NKG2C+ imprinted memory-like NK cells that differentiate following CMV infection [31–33]? The finding that virus-induced NK cell memory requires proinflammatory cytokines such as IL-12 [30, 37] suggests that cytokine receptor signaling may be a common pathway central to the generation of innate NK cell memory. Furthermore, the preservation of enhanced CIML NK cell functionality following multiple rounds of cell division [38, 41] suggests that epigenetic alterations may contribute to CIML NK cell differentiation and function. Indeed, epigenetic changes have been observed in cytokine-preactivated and NKG2C+ imprinted human NK cells, reinforcing a potential role for epigenetic imprinting in NK cell memory [60–62]. An improved understanding of human CIML NK cell biology will be important to expand the clinical potential and spectrum of NK cell memory. We are hopeful that as our understanding of CIML NK cell biology expands, we will translate these findings to better outcomes for cancer patients.

Acknowledgments

We thank Drs. Megan Cooper, Rizwan Romee, Wayne Yokoyama, Anthony French, and all members of the Fehniger lab for insightful discussion. This work was supported by the Siteman Cancer Center/Cancer Frontier Fund at Washington University (T.A.F.), Gabrielle’s Angel Foundation for Cancer Research (T.A.F.), R01AI102924 (T.A.F.) and the Washington University Institute of Clinical and Translational Sciences grants UL1 TR000448 and TL1 TR000449 from the National Center for Advancing Translational Sciences (J.A.W.).

References


